Top Telehealth Companies (1,098)

Strong Revenue Growth: Revenue is reported to have grown at a robust compound rate over multiple years, with momentum described as accelerating as of 2026. Company updates and industry reporting consistently point to ongoing top-line expansion alongside network scale-up.

Profitability: The company indicates it has been annually profitable since 2023 and cash-flow positive, and it cites performance above the 'Rule of 40' benchmark in 2025. This signals growth paired with financial discipline rather than expansion funded by sustained losses.

Strategic Partnerships: The Care Access Network extends booking into platforms including Amazon Health AI, Google Gemini, Yelp, Healthgrades, and Blue Shield of California. Partner implementations are described as materially increasing booked appointments and expanding available bookable hours, indicating traction beyond the core site.

Healthy Cash Flow: Free cash flow reached $317.5M in FY2026, up 19% year over year, underscoring strong cash generation. Operating cash flow also increased 19% to $326.5M, indicating robust cash conversion.

Profitability: Operating profitability expanded in FY2026, with adjusted EBITDA rising 14% to $357.8M. This points to solid earnings power alongside multi‑year revenue growth.

Strong Market Position & Advantage: Platform reach includes more than 85% of U.S. physicians, and workflow‑active prescribers grew 30%+ year over year. AI Search queries also rose more than 25% quarter over quarter, evidencing deepening engagement.

Strong Revenue Growth: Historical revenue acceleration is underscored by a top-50 placement on the 2026 Inc. 5000 and reported 2025 profitability, pointing to substantial commercial momentum.

Investor Backing & Capital Strength: Successive venture rounds culminating in a $100 million Series C and approximately $215 million total funding indicate deep capital support for expansion into AI, provider capacity, and broader metabolic care.

Market Expansion: Reported nationwide availability includes access to over 200 million covered lives, a network exceeding 10,000 registered dietitians, and more than 500,000 patients served, signaling rapid scaling of distribution and capacity.

Strong Revenue Growth: A sixfold year-over-year revenue increase was reported in May 2025, indicating rapid commercial momentum. Rising visit volumes from roughly 5,000 in 2022 to 125,000+ in 2025 further reinforce this trajectory.

Market Expansion: Operations expanded from five states in 2023 to 18 by May 2025 and to nearly 25 states by February 2026. Coverage increasingly spans Medicare, Medicaid, and Marketplace populations, widening the addressable market.

Investor Backing & Capital Strength: A $55 million Series B in May 2025 brought total funding above $125 million, led by prominent investors. This capital base supports ongoing technology, staffing, and multistate rollout.

Market Expansion: Service availability is described across all 50 states with new local launches and roles dedicated to opening regional provider partnerships. This points to broadening geographic reach and distribution through healthcare and senior-care channels.

Product Line Growth: The platform has expanded beyond therapy to include healthcare advocacy, wellness classes, and AI-enabled care agents. These additions indicate a widening offering to address aging-related needs.

Strong Hiring & Retention: Active recruitment spans engineering, operations, analytics, revenue-cycle management, and provider-partnerships to scale care delivery. Such hiring momentum suggests investment in internal capacity to support larger patient and provider volumes.

Investor Backing & Capital Strength: A $50 million financing package in April 2025—described as oversubscribed and comprising $30 million in equity and $20 million in credit—signals strong access to capital for scaling. This followed a $32 million Series A in 2024, indicating continued investor support.

Strategic Partnerships: Partnerships announced in 2026 with PrismHR and entry into the Workday Wellness Program extend distribution through established HR ecosystems, creating access to broad employer networks. These relationships add go-to-market channels beyond direct sales.

Innovation-Driven Growth: New offerings in 2025–2026—such as AI-powered claims analytics, Zoe for HR, and a cash-pay care network—indicate active product expansion. Integrations that bring Zoe to Slack and Microsoft Teams further broaden usage contexts and signal ongoing investment in product breadth.

Strong Revenue Growth: Revenue is described as having grown more than 300% in 2024 and doubling again in 2025, with Inc.’s 2026 profile citing 830% three-year growth. Together these signals point to rapid top-line acceleration.

Investor Backing & Capital Strength: Capital raised totals $162 million, including a $72 million Series C in May 2025. Fortune reported participation from major insurers and financial institutions, indicating sustained investor confidence.

Strategic Partnerships: Partnerships span dozens of carriers and employers, including a majority of the top 10 U.S. life insurers and new launches such as Zurich in the UK and collaborations with MetLife, Principal, TD Bank, and Transamerica. Distribution is primarily enterprise-based, supporting scaled access to tens of millions of eligible users.

Strong Revenue Growth: Independent estimates point to a substantial increase in annualized revenue in 2024, reflecting accelerating business volume. While later-year figures are not confirmed, the trajectory suggests meaningful top-line momentum.

Market Expansion: The rollout of covered therapy and psychiatry nationwide, alongside a materially larger provider network, indicates broadening geographic reach and capacity. These moves increase addressable demand and operating scale.

Strategic Partnerships: Collaborations with Amazon Health Services and other digital health platforms extend distribution and can streamline patient intake and insurance workflows. Such partnerships expand the potential patient pipeline even if direct conversion impacts are not disclosed.

Strong Revenue Growth: Inc.’s 2026 company profile indicates multi‑year revenue expansion and repeated placement on a national fast‑growth list. Continued recognitions suggest ongoing top‑line momentum even without public audited figures.

Market Expansion: Acquisition activity, including the 2025 purchase of Joshin, and reported reach across employers, providers, and education point to a broader commercial footprint. New executive appointments and product initiatives in 2026 further signal an expansion push.

Diversified Revenue Streams: Offerings span behavioral‑health providers (RethinkBH), employer well‑being and neurodiversity (RethinkCare), education (RethinkEd), and analytics for payers (RethinkFutures). Reported adoption across these segments indicates multiple avenues for monetization.

Strong Revenue Growth: Sacra estimates indicate revenue rose from about $360M in 2023 to roughly $598M in 2024, a sharp increase attributed largely to Ro Body. This points to accelerated top-line momentum rather than mere product proliferation.

Market Expansion: Launches such as the nationwide Wegovy pill on January 5, 2026 and additional obesity-care offerings suggest broader reach across treatment categories and patient segments. Reuters also describes an influx of new customers with the oral Wegovy launch, including men who avoided injections.

Strategic Partnerships: Announcements document direct collaborations with Novo Nordisk on Wegovy and Eli Lilly on Zepbound, alongside a research tie-up with Amgen. These relationships expand access to branded therapies and reinforce distribution relevance in obesity care.

Product Line Growth: Product offerings are expanding with the 2025 launch of an end-to-end Navigator platform and new AI wellness and behavioral-health agents. Available information indicates these capabilities are being rolled out to existing and prospective health-plan partners.

Market Expansion: Geographic and segment reach is broadening through a Brazil partnership and a strategic engagement with a national employer-focused care-management organization in the United States. These moves suggest ongoing efforts to extend distribution across payers, employers, and new use cases.

Strategic Partnerships: Partnership activity, including collaborations with firms such as FCamara and other healthcare organizations, is portrayed as a key lever to scale adoption. Feedback suggests these alliances are intended to accelerate deployment and diversify channels across regions.